US EditionBreakthrough ASCO Data: Innovent's HER2 Drug Achieves 72% Response in Breast Cancer, Shows Promise in Ovarian Cancer
- Innovent Biologics announced updated Phase 1/2 clinical data for IBI354, a HER2-targeted ADC, at the 2025 ASCO Annual Meeting on June 2, 2025, from San Francisco and Suzhou, China.
- A total of 368 participants diagnosed with advanced solid tumors—including breast and ovarian cancer—were recruited to assess the safety, tolerability, and initial efficacy of varying doses of IBI354.
- IBI354 demonstrated a 59.1% objective response rate and 90.9% disease control rate in 88 HER2-positive breast cancer patients, with a 72.4% ORR in the 9 mg/kg subgroup and median progression-free survival of 14.1 months.
- In the 92-patient platinum-resistant ovarian cancer cohort, IBI354 achieved a 41.2% confirmed ORR and 82.0% DCR, with a 55.0% ORR in the 12 mg/kg subgroup and a favorable safety profile marked by low incidence of interstitial lung disease .
- These results support further development of IBI354, including a Phase 3 trial in platinum-resistant ovarian cancer, and illustrate Innovent's advancement in next-generation ADC therapies characterized by high potency and low toxicity.
Insights by Ground AI
Does this summary seem wrong?
26 Articles
26 Articles
All
Left
3
Center
9
Right
Aspen Daily News+24 Reposted by 24 other sources
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…
Coverage Details
Total News Sources26
Leaning Left3Leaning Right0Center9Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
